Community-acquired Pneumonia Clinical Trial
Official title:
Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis
The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication
used to treat gastric conditions, increase the risk of hospitalization for community-acquired
pneumonia (HCAP).
The investigators will carry out separate population-based cohort studies using
administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort
entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with
follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results
from the separate sites will be combined using a statistical approach called meta-analysis to
provide an overall assessment of the risk of HCAP with PPIs.
Previous observational studies have found an association between proton pump inhibitors
(PPIs), a class of medications used to treat gastric conditions, and the risk of community
acquired pneumonia. These studies, however, had important limitations including confounding
by indication and protopathic bias. The purpose of this study is to determine whether PPIs
increase the risk of hospitalization for community-acquired pneumonia (HCAP). To overcome the
limitations of previous studies that examined this issue, this study will be conducted in a
cohort of new users of non-steroidal anti-inflammatory drugs (NSAIDs), in whom PPIs are often
prescribed prophylactically to prevent dyspepsia and other gastric side effects.
The investigators will use a common-protocol approach to conduct retrospective cohort studies
using administrative health care data from eight jurisdictions (the Canadian provinces of
Alberta, Saskatchewan, Manitoba, Ontario, Quebec, and Nova Scotia, as well as the United
States (US) MarketScan, and the United Kingdom (UK) General Practice Research Database
[GPRD]). Briefly, the Canadian databases include population-level data on physician billing,
diagnoses and procedures from hospital discharge abstracts, and dispensations for
prescription drugs. Alberta, Nova Scotia, Ontario, and Quebec data will be restricted to
patients aged 65 years and older as prescription data are not available for younger patients.
For Quebec, a 10% random sample of eligible patients will be used. The GPRD is a clinical
database that is representative of the UK population and contains the records for patients
seen at over 680 general practitioner practices in the UK. US MarketScan includes individuals
and their dependents covered by large U.S. employer health insurance plans, and government
and public organizations. As Medicare eligibility begins for those above the age of 65, the
US MarketScan data will be restricted to patients aged 40 to 65 years in order to ensure
complete data capture.
In each jurisdiction, the investigators will assemble a source population that includes all
patients with a prescription for an oral NSAID (WHO Anatomical Therapeutic Chemical (ATC)
Code M01A). From this source population, a study cohort will be created including all
patients who received a prescription for an oral NSAID of ≥ 30 days duration, as patients
receiving short duration prescriptions are unlikely to be prescribed a PPI for prophylactic
reasons. The date of prescription (for the GPRD) or dispensation (for all other sites) of the
oral NSAID will define the date of study cohort entry.
Patients will be followed from the date of study cohort entry until an event (defined below)
or censoring due to death, departure from the database, end of follow-up (180 days), or the
end of the study period (September 30, 2011 or the last date of data availability at that
site), whichever occurs first. Patients will be permitted to enter the cohort multiple times
provided that all inclusion criteria are met.
The investigators will create three mutually exclusive exposure categories: 1) PPI users, 2)
H2RA users, and 3) unexposed patients. The investigators will use an analysis analogous to an
intention-to-treat approach. Exposure to PPIs will be defined as a prescription for a PPI
(esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole) on the same day as their
cohort entry defining prescription for an NSAID. Exposure to H2RAs will be defined as a
prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine,
roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine
combinations) on the same day as their cohort entry defining prescription for an NSAID.
Patients that are considered to be unexposed will be defined as patients not prescribed a PPI
or H2RA on the same day as their cohort entry defining prescription for an NSAID. The primary
outcome will be defined as incident HCAP during the 6 months following initiation of NSAID
therapy.
Multiple logistic regression will be used to estimate site-specific adjusted odds ratios
(aORs) and corresponding 95% confidence intervals (CIs) for the association of incident HCAP
at 6 months and PPI exposure. This is considered the primary analysis. Several sensitivity
analyses will be performed to assess the robustness of study results. Such analyses include:
restricting analyses to a single, random, observation per patient; excluding patients who
received a prescription for a PPI, H2RA, or NSAID in the 12 months before cohort entry; and
excluding crossovers between PPI and H2RAs. High dimensional propensity scores will be
estimated for all patients in the cohort using logistic regression. Finally, all
site-specific estimates will be meta-analyzed using fixed models with inverse variance
weighting. The amount of between-site heterogeneity will be estimated using the I-squared
statistic.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05722938 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
|
Phase 3 | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Recruiting |
NCT06065618 -
Characteristics of Hospitalized Patients With Community-acquired Pneumonia
|
||
Not yet recruiting |
NCT03675178 -
Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia
|
Phase 4 | |
Not yet recruiting |
NCT04166110 -
Antibiotic Therapy In Respiratory Tract Infections
|
N/A | |
Completed |
NCT02380352 -
Short-course Antimicrobial Therapy for Paediatric Respiratory Infections
|
Phase 4 | |
Completed |
NCT01671280 -
Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
|
N/A | |
Recruiting |
NCT00752947 -
Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors
|
Phase 4 | |
Completed |
NCT00140023 -
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
|
Phase 3 | |
Recruiting |
NCT04089787 -
Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia
|
Phase 4 | |
Completed |
NCT05356494 -
Postural Drainage and PEP Technique in Community Acquired Pneumonia
|
N/A | |
Completed |
NCT05133752 -
Oral Nemonoxacin in Treating Elderly Patients With CAP
|
Phase 4 | |
Not yet recruiting |
NCT06291012 -
Stopping Pneumonia Antibiotherapy Regimen Early
|
Phase 4 | |
Recruiting |
NCT05002192 -
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
|
||
Completed |
NCT03452826 -
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
|
N/A | |
Terminated |
NCT04071041 -
Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
|
Phase 3 | |
Completed |
NCT03474991 -
KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP
|
Phase 3 | |
Completed |
NCT01723644 -
Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia
|
N/A | |
Withdrawn |
NCT01662258 -
Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP
|
N/A | |
Completed |
NCT01683487 -
Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.
|
Phase 4 |